Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC).

被引:0
|
作者
Baran, R
McKenna, E
Patt, Y
Ghali, N
机构
[1] Roche Biomed Labs, Nutley, NJ USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3762
引用
收藏
页码:309S / 309S
页数:1
相关论文
共 50 条
  • [41] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] SURGICAL RESECTION OF METASTASES (MTS) AFTER BIWEEKLY CHEMOTHERAPY WITH IRINOTECAN, OXALIPLATIN AND 5-FLUOROURACIL/LEUCOVORIN (FOLFOXIRI) IN INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Masi, G.
    Cupini, S.
    Marcucci, L.
    Cerri, E.
    Loupakis, F.
    Allegrini, G.
    Ricci, S.
    Brunetti, I.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 66 - 67
  • [43] Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost Comparison
    Chu, Edward
    Schulman, Kathy L.
    McKenna, Edward F., Jr.
    Cartwright, Thomas
    CLINICAL COLORECTAL CANCER, 2010, 9 (04) : 229 - 237
  • [44] Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC).
    Falcone, A
    Masi, G
    Cupini, S
    Marcucci, L
    Ricci, S
    Brunetti, I
    Cerri, E
    Fontana, E
    Andreuccetti, M
    Allegrini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 258S - 258S
  • [45] A pilot study of irinotecan combined with 5-fluorouracil and leucovorin (FOLFIRI) for the treatment of Chinese patients with locally advanced and metastatic gastric cancer
    Li, Q.
    Chen, J.
    Zhao, X.
    Yin, X.
    Mai, K.
    Chengya, Z.
    Cai, X.
    ANNALS OF ONCOLOGY, 2008, 19 : 43 - 43
  • [46] IRINOTECAN WITH BIWEEKLY, LOW DOSE LEUCOVORIN AND BOLUS AND CONTINUOUS INFUSION 5-FLUOROURACIL (MODIFIED FOLFIRI) AS FIRST LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER
    Oh, S. Y.
    Kim, B. G.
    Kwon, H.
    Lee, S.
    Lee, D. M.
    Jang, J. S.
    Kim, M. C.
    Kim, S.
    Kim, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 183 - 183
  • [47] First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
    Cassidy, J
    Twelves, C
    Van Cutsem, E
    Hoff, P
    Bajetta, E
    Boyer, M
    Bugat, R
    Burger, U
    Garin, A
    Graeven, U
    McKendrick, J
    Maroun, J
    Marshall, J
    Osterwalder, B
    Pérez-Manga, G
    Rosso, R
    Rougier, P
    Schilsky, RL
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 566 - 575
  • [49] Randornised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
    Nogué, M
    Salud, A
    Batiste-Alentorn, E
    Saigí, E
    Losa, F
    Cirera, L
    Méndez, M
    Campos, JM
    Galan, A
    Escudero, P
    Arcusa, A
    Manzano, H
    de Mendizábal, EV
    de Olaguer, JP
    Boleda, M
    Guasch, I
    Vicente, P
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (15) : 2241 - 2249
  • [50] First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
    Claus-Henning Köhne
    Ralf Hofheinz
    Laurent Mineur
    Henry Letocha
    Richard Greil
    Josef Thaler
    Eva Fernebro
    Erick Gamelin
    Lucy DeCosta
    Meinolf Karthaus
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 65 - 72